BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2016 3:43:00 PM | Browse: 842 | Download: 1513
 |
Received |
|
2016-08-02 09:33 |
|
Peer-Review Started |
|
2016-08-03 11:23 |
|
To Make the First Decision |
|
2016-08-22 14:27 |
|
Return for Revision |
|
2016-08-24 19:08 |
|
Revised |
|
2016-09-09 00:16 |
|
Second Decision |
|
2016-09-21 15:02 |
|
Accepted by Journal Editor-in-Chief |
|
2016-09-21 15:38 |
|
Accepted by Company Editor-in-Chief |
|
2016-10-19 17:11 |
|
Articles in Press |
|
2016-10-19 17:11 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-10-31 09:15 |
|
Publish the Manuscript Online |
|
2016-11-06 15:43 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Giovanni Dothel, Emanuel Raschi, Roberto Rimondini and Fabrizio De Ponti |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fabrizio De Ponti, MD, PhD, Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio, 48, I-40126 Bologna, Italy. fabrizio.deponti@unibo.it
|
| Key Words |
Mesenchymal stromal cells; Mesenchymal stem cells; Inflammatory bowel diseases; Intestinal disorders; Translational medicine |
| Core Tip |
mesenchymal stromal cells (MSCs) release immunomodulatory mediators upon inflammatory stimuli. This behavior is attractive for the development of advanced therapeutic strategies applied to several intestinal disorders where inflammation is a key pathophysiological feature. In order to assess quality, efficacy and safety of MSC-based therapy, a novel approach to pharmacokinetics/pharmacodynamics (PK/PD) is mandatory. This must rely on careful assessment of cell phenotype, signaling and homing mechanisms. In this regard, experimental models must take advantage of the most updated knowledge in order to reflect the PK/PD mechanisms in humans. Finally, an alternative approach to the “whole-cell treatment” applies MSC-derived mediators alone in order to avoid the hypothesized serious adverse events deriving from a biological entity mostly acting systemically.
|
| Publish Date |
2016-11-06 15:43 |
| Citation |
Dothel G, Raschi E, Rimondini R, De Ponti F. Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology. World J Gastroenterol 2016; 22(41): 9057-9068 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i41/9057.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i41.9057 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
